Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2015-03-17 / Biol. Pharm. Bull. 2015;38(6):827-35Transplanted tumor growth and the incidence of T-lymphocyte populations in the spleen of newcastle virus-treated mice
/in International Publications, Newcastle Disease Virus /von 2015-03-12 / Cancer Biother. Radiopharm. 2015 May;30(4):182-6Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models
/in International Publications, Newcastle Disease Virus /von 2015-03-11 / Mol. Cancer Ther. 2015 May;14(5):1247-58Cancer immunotherapy: dendritic-cell vaccines on the move
/in Dendritic Cells, International Publications /von 2015-03-11 / Nature 2015 Mar;519(7543):300-1A novel cancer immunotherapy based on the combination of a synthetic carbohydrate-pulsed dendritic cell vaccine and glycoengineered cancer cells
/in Dendritic Cells, International Publications /von 2015-03-10 / Oncotarget 2015 Mar;6(7):5195-203Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2015-03-09 / Cancer Sci. 2015 Apr;106(4):397-406Immunotherapy for lung cancer: for whom the bell tolls?
/in Dendritic Cells, International Publications, NSCLC /von 2015-03-04 / Tumour Biol. 2015 Mar;36(3):1411-22Dendritic cell-based vaccine efficacy: aiming for hot spots
/in Dendritic Cells, International Publications /von 2015-03-03 / Front Immunol 2015;6:91Inhibitory and apoptosis-inducing effects of Newcastle disease virus strain AF2240 on mammary carcinoma cell line
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2015-03-02 / Biomed Res Int 2015;2015:127828
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution